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Abstract
Respiratory muscle dysfunction may develop rapidly in
critically ill ventilated patients and is associated with
increased morbidity, length of intensive care unit stay,
costs, and mortality. This review briefly discusses the
pathophysiology of respiratory muscle dysfunction in
intensive care unit patients and then focuses on
strategies that prevent the development of muscle
weakness or, if weakness has developed, how
respiratory muscle function may be improved. We
propose a simple strategy for how these can be
implemented in clinical care.
Background
Respiratory muscle weakness may develop in ventilated
critically ill patients [1–4]. For instance, Jaber and
colleagues [1] demonstrated that after 5–6 days of
controlled mechanical ventilation in intensive care
unit (ICU) patients, force-generating capacity of the
diaphragm was reduced by ±32 %. In ICU patients,
impaired capacity of the respiratory muscles is
accompanied by an increased load due to elevated
elastic and resistive forces of the respiratory system.
This imbalance in load and capacity plays an import-
ant role in the development of ventilatory failure, for
instance during a weaning trial. Respiratory muscle
weakness is associated with adverse clinical outcomes,
including difficult weaning from mechanical ventila-
tion, increased mortality, and increased risk of ICU/
hospital readmission [5]. It is reasonable to propose
that strategies that aim to restore respiratory muscle
function in these patients improve outcome. The aim
of this review is to discuss (future) strategies that
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prevent the development of respiratory muscle weakness
or restore respiratory muscle function in weak ICU
patients. We will mainly focus on interventions that
are most likely to be of clinical importance in the
near future.
Pathophysiology of respiratory muscle weakness
in the critically ill
Reduced force output of the respiratory muscles in the
critically ill may result from injury at any point between
the central respiratory centers and the contractile pro-
teins of diaphragm muscle fibers [6, 7]. In the absence of
sedatives, reduced central respiratory drive is unlikely to
explain reduced force output of the respiratory muscles
in ICU patients [8]. Phrenic nerve neuropathy, as
assessed by prolonged phrenic nerve conduction time,
has been demonstrated in ICU patients, indicating that
injury of the peripheral nerve may play a role in reduced
force output [9].
Contractile dysfunction of the respiratory muscles in
ICU patients may result from the loss of muscle mass
(atrophy) and/or dysfunction of the remaining contract-
ile proteins. In a landmark paper, Levine and colleagues
[10] demonstrated the rapid development of diaphragm
muscle atrophy in ventilated brain-dead patients. More
recently, Hooijman and colleagues [11] performed in-
depth functional and structural analysis of diaphragm
biopsies in critically ill patients on the ventilator. In that
study, muscle fiber cross-sectional area was reduced by
±25 % after an average of 7 days of mechanical ventila-
tion. Muscle atrophy is the final result of an imbalance
between protein synthesis and degradation. Upregulation
of several proteolytic pathways has been demonstrated
in the respiratory muscles of ICU patients [11]. For
instance, key regulators of the ubiquitin-proteasome
pathway are upregulated in the diaphragm of these pa-
tients [10, 11]. Other pathways such as lysosomal
protein degradation and autophagy may play a role as
well (Fig. 1) [12, 13]. In addition to enhanced proteolysis,
© 2016 Schellekens et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schellekens et al. Critical Care  (2016) 20:103 
DOI 10.1186/s13054-016-1280-y
decreased protein synthesis has been reported in the dia-
phragm of rodents subjected to controlled mechanical
ventilation [14, 15]. Besides atrophy, diaphragm weakness
may be the result of contractile protein dysfunction. Even
when corrected for loss of protein, muscle fibers in ICU
patients develop less force [4]. Furthermore, the sensitivity
of the contractile proteins for calcium is reduced [4]. The
pathophysiology of contractile protein dysfunction in
these patients is incompletely understood, but animal
models of mechanical ventilation and endotoxemia indi-
cate that phosphorylation and oxidative modifications of
the sarcomeric proteins and mitochondrial proteins play a
role in dysfunction and injury [16–19]. For an extensive
background on the pathophysiology of muscle dysfunction
in the critically ill, we refer to a recent excellent review on
this subject [20].
Evaluation of respiratory muscle function in ICU
patients
We will briefly discuss the readily available techniques
that are relevant and feasible in clinical practice. For a
detailed overview we refer to other reviews [21–23].
Maximal inspiratory pressure (MIP) and maximal expira-
tory pressure (MEP) are used to evaluate global respira-
tory muscle strength and can be applied to selected ICU
patients. MIP and MEP are measured using a handheld
pressure device connected to the endotracheal tube or
tracheostomy while the patient performs specific maneu-
vers. Although American Thoracic Society/European Re-
spiratory Society guidelines advise a single inspiratory
maneuver at residual volume in non-intubated patients
[24], the reliability of MIP measurement in ICU patients
is improved when using a unidirectional expiratory
Fig. 1 Proposed scheme of pathophysiologic pathways in the development of respiratory muscle weakness during critical illness. Oxidative stress
[89], inflammation [71, 74], increased nuclear factor (NF)-κB activity [90], and mechanical unloading [10, 11] have been proposed to initiate
respiratory muscle weakness. These initiators can result in contractile protein becoming dysfunctional [4], decreased synthesis [14, 15], or muscular
autophagy [12]. Oxidative stress and inflammatory pathways can activate caspases and calpains [89, 91], thereby delivering substrates for the
ubiquitin-proteasome [10, 11, 92], which further degrades contractile proteins
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valve connected to the endotracheal tube or tracheos-
tomy [25]. Alternatively, pressures can be assessed
using the ventilator by performing an end-expiratory
hold maneuver. A 20-s end-expiratory occlusion can be
performed to obtain more reliable measurements in
poorly cooperative patients [26]. It should be acknowl-
edged that assessment of MIP and MEP requires a co-
operative patient. Today, most ICU ventilators provide
automatic functions to provide some useful parameters
to evaluate the diaphragm function. High values for
MIP and MEP exclude clinically significant weakness,
but low values are common and may also reflect poor
technique or effort [27].
Esophageal pressure (Pes) is an estimate of pleural
pressure [28] and can be used to calculate the amount
of work performed by the respiratory muscles. Simul-
taneous recording of Pes and gastric pressure (Pga)
allows the calculation of transdiaphragmatic pressure
(Pdi = Pga − Pes), a specific measure of diaphragm con-
tractility. The latter is useful for close monitoring and
evaluation of diaphragm function in difficult-to-wean
patients [29]. However, acquisition, calculation, and
interpretation of Pes, Pga, and their derived measures
are rather complex and therefore not widely accepted
in clinical practice.
Ultrasonography is an increasingly popular tool for
assessment of diaphragm function in ICU patients [30].
In the subcostal view reduced caudal movement of the
diaphragm during unassisted breathing is consistent
with weakness and paradoxal movement indicates
diaphragm paralysis [31, 32]. Diaphragm atrophy can
be assessed by measuring diaphragm thickness in the
midaxillary line at the level of the diaphragm dome
[32, 33] and its thickening fraction during inspiration
to asses contractile activity [30]. Diaphragm atrophy
can also be evaluated more precisely with computed
tomography, although this is more cumbersome than
echography [34]. Using ultrasound, Goligher and col-
leagues [30] recently demonstrated in ICU patients
that diaphragm atrophy is associated with diaphragm
dysfunction and, in a minority of these patients, dia-
phragm thickness surprisingly increased while on the
ventilator, which was associated with dysfunction as
well. Diaphragm electromyography (EMG) reflects
the electrical activity and is the gold standard to as-
sess neural respiratory drive. Diaphragm EMG can be
recorded best using an esophageal catheter with mul-
tiple electrodes. With the introduction of neurally
adjusted ventilatory assist (NAVA; Maquet, Solna,
Sweden) [35], the (processed) EMG signal can be
obtained continuously in ICU patients. In these patients,
diaphragm EMG may be used to monitor respiratory
muscle unloading [36] and patient–ventilator inter-
action [37].
Modulation of contractile activity: disuse and
inspiratory muscle training
Prevention of disuse atrophy
Like any other striated muscle, respiratory muscle mass
is affected by contractile inactivity. In fact, the respira-
tory muscles appear more sensitive to the effects of dis-
use compared with other striated muscles [10, 11, 34].
In humans, relatively brief periods of diaphragm disuse
(<3 days) due to controlled mechanical ventilation are
associated with diaphragm muscle fiber atrophy [10].
Animal studies have demonstrated that mechanical
ventilation-induced diaphragm atrophy and dysfunction
is less severe in assisted modes of mechanical ventilation
[38]. Recently, Goligher et al. [30] used ultrasound tech-
niques to demonstrate that low levels of diaphragm ac-
tivity, resulting from high levels of ventilator support,
are associated with diaphragm atrophy and dysfunction
in ICU patients. On the other hand, administration of
muscle relaxants for 48 h in patients with early severe
acute respiratory distress syndrome (ARDS) resulted in
earlier withdrawal from mechanical ventilation and did
not adversely affect peripheral muscle function [39].
Therefore, it appears that, under certain conditions (i.e.,
very severe ARDS), controlled mechanical ventilation is
preferred to facilitate lung-protective ventilation and this
beneficial effect outweighs the possible adverse effects
on the respiratory muscles. Nevertheless, in general it is
reasonable to limit the duration of controlled mechan-
ical ventilation and prevent high levels of support under
assisted ventilation in order to reduce the risk of disuse
atrophy [10, 30, 40]. It is important to recognize that
ventilator pressure and flow waveforms are unreliable
to confirm the presence of respiratory muscle activity
[21, 22, 41]. We recommend additional monitoring
techniques as outlined above. Although the optimal
level of activity for the respiratory muscles is unknown
during mechanical ventilation, these monitoring tech-
niques allow us to detect complete inactivity of the mus-
cles due to over-assist.
Inspiratory muscle training
In general, training can be instituted to enhance muscle
endurance or strength. These types of training require
different strategies and have distinct physiological re-
sponses. In healthy subjects, respiratory muscle activity
is characterized by development of low pressure during
the entire life span of a subject. The pressure generated
by the inspiratory muscles is only ±5 cmH2O (5 % of
maximum inspiratory pressure) to generate a tidal
volume of 500 ml, when respiratory compliance is
100 ml/cmH2O. At first sight, training of the respira-
tory muscle should, therefore, be designed to improve
endurance. Indeed, in patients who are difficult to wean
from the ventilator, progressive weaning trials (T-tube
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or low pressure support) are frequently instituted as
training stimulus. Although reasonable from a physio-
logical perspective, it has never been proven that this
strategy indeed improves respiratory muscle endurance.
In very few circumstances is high inspiratory pressure
required for prolonged periods of time and therefore
strength training of the diaphragm seems of limited
relevance. It has been demonstrated, however, that
respiratory effort sensation depends on the maximal
inspiratory pressure [42]. In healthy subjects, pharma-
cological induction of inspiratory muscle weakness in-
creases respiratory effort sensation for the same workload
[42], confirming the importance of adequate strength
beyond that strictly required to generate tidal volume.
It has been shown that inspiratory muscle strength
training (IMST) improves whole body exercise per-
formance, in particular in less fit subjects [43]. Also,
in patients with chronic obstructive pulmonary dis-
ease (COPD), IMST improves inspiratory muscle
strength and total body exercise and reduces dyspnea
sensation [44]. Only three randomized studies have
reported the effectiveness of IMST in ventilated ICU
patients. In the trial by Cader et al. [45], 41 ventilated
ICU patients with respiratory muscle weakness were
randomized between inspiratory threshold loading and
no training intervention. Training consisted of an in-
spiratory load of 30 % maximum inspiratory pressure
for 5 minutes, twice a day, 7 days a week throughout the
weaning period. Maximum inspiratory pressure was sig-
nificantly increased in the training group (15 ± 3 to 25 ± 4
cmH2O) but not in the control group (15 ± 2 to 18 ± 2
cmH2O). The study was underpowered for clinically rele-
vant endpoints, although weaning time was reduced in the
training group. In another study, Martin and colleagues
[46] randomized 69 ventilator-bound patients (mean dur-
ation of ventilation at inclusion ±44 days) to IMST or
sham training added to endurance training. Strength
training consisted of four sets of 6–10 breaths per
day with 2 minutes rest between each set. Loading
was individualized and set at a level that could just
be tolerated by the patient. IMST significantly improved
maximum inspiratory pressure (end of training 54 cmH2O
in intervention group and 45 cmH2O in sham group,
P < 0.05). Also, successful weaning at day 28 after in-
clusion was more likely in the intervention group
compared with sham (71 versus 47 %, P < 0.05). No
adverse events of IMST were reported in these two
trials. Finally, Condessa et al. [47] randomized ventilated
patients to inspiratory strength training on top of usual
care versus usual care only. Each training session con-
sisted of five sets of loaded breaths (40 % maximum in-
spiratory pressure), twice a day, 7 days a week. In this
study, IMST significantly increased maximum inspiratory
pressure but did not affect weaning time.
In conclusion, inspiratory muscle training is feasible
and appears safe in patients with respiratory muscle
weakness who are difficult to wean from the ventilator,
which is supported by a recent systematic review [48].
Studies in other patient categories, including COPD, in-
dicate that IMST improves outcome. In our opinion, it
is reasonable to add IMST to endurance training in
stable, difficult-to-wean patients with confirmed respira-
tory muscle weakness. Future studies are needed to de-
termine the optimal training protocol and appropriate
timing for initiation of IMST.
Antioxidants and nutrition
As outlined above, oxidative stress may play a role in the
pathophysiology of ICU-acquired respiratory muscle
weakness. Several experimental studies demonstrate
that antioxidants attenuate the detrimental effects of
controlled mechanical ventilation and/or systemic
inflammation on respiratory muscle structure and function
[18, 49–51]. In healthy subjects, high dose N-acetylcysteine
(150 mg/kg intravenously) attenuated diaphragm fatigue
induced by an inspiratory resistive load [52]. Today, no
study has specifically evaluated the effect of antioxidants
on respiratory muscle function in ICU patients; however,
some indirect evidence is available. In an open trial, 595
critically ill surgery or trauma patients were randomized
between antioxidant supplementation (alpha-tocopherol
and ascorbic acid) and standard care or standard care only
[53]. Patients in the antioxidant group spent less time on
the ventilator (3.7 versus 4.6 days, P < 0.05). It should be
noted that patients in this study were young (38 ± 15 years)
and total ventilation time was rather short. Therefore, it is
questionable whether the beneficial effects of antioxidants
were the result of improved respiratory muscle function.
Heyland et al. [54] studied the effects of antioxidants and
glutamine in a heterogeneous ICU population (N = 1223).
Patients were divided into four groups: placebo, glutamine
(0.35 g/kg/24 h of body weight intravenously), antioxidants
(selenium, zinc, beta carotene, vitamin E, and vitamin C),
or antioxidants plus glutamine. Again, respiratory muscle
function was not specifically evaluated but no difference in
duration of mechanical ventilation was observed among
the four groups.
Today, only one study has evaluated the effects of two
nutritional strategies on skeletal muscle structure and
function in critically ill patients [55]. This study was a
planned subanalysis of the EPaNIC trial that compared
the effects of tolerating macronutrient deficiency versus
early parenteral nutrition on skeletal muscle structure
and function [56]. In that study, patients were randomized
between early (within 2 days of ICU admission) versus late
(<8 days after ICU admission) parenteral nutrition to pre-
vent macronutrient deficiency. Skeletal muscle strength
was assessed in 600 ICU patients using the Medical
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Research Council sum score. Weakness occurred less
often in the late versus early parenteral nutrition group
(34 versus 43 %, P = 0.030). Compared with healthy sub-
jects, muscle fibers exhibited atrophy but were not signifi-
cantly different between the early and late parenteral
nutrition groups. However, markers for autophagosome
formation were significantly higher in the late parenteral
nutrition group. This indicates that autophagy plays an
important role in protein turnover next to other effects to
provide substrate for recycling. In conclusion, tolerating
macronutrient deficiency in the first week after ICU ad-
mission is not associated with the development of muscle
fiber atrophy but surprisingly appears to improve muscle
contractility.
Although the effect of high-dose antioxidant administra-
tion on respiratory muscle structure and function is en-
couraging in animal models, no data support the routine
administration of antioxidants or other specific feeding
strategies on respiratory muscle function in the critically
ill ventilated patient.
Improving respiratory muscle protein content:
anabolics
Loss of muscle mass plays an important role in the de-
velopment of ICU-acquired respiratory muscle weakness
[10, 11]. Pharmacological interventions that restore pro-
tein balance seem a reasonable approach in these pa-
tients. First, inhibitors of proteolysis increase respiratory
muscle mass in animal models with heart failure and
under mechanical ventilation [57, 58] but toxicity limits
the application of these agents for this specific indication
in humans. Second, anabolic hormones have been used
to enhance skeletal muscle mass under a variety of
conditions (reviewed in [59]). We focus on the effects
of endogenous and exogenous anabolic hormones on
the respiratory muscles.
The most important endogenous anabolic hormones
are growth hormone (GH), insulin-like growth factor-1
(IGF-1), insulin, and the anabolic steroid testosterone
and its analogues. The effects of GH on skeletal muscle
have been reviewed recently [60]. GH enhances produc-
tion of IGF-1 in the liver but has direct anabolic effects
on skeletal muscle as well. The effect of administration
of GH/IGF-1 or its exogenous analogues on respiratory
muscle function in critically ill patients has not been
studied. However, Takala et al. [61] reported the effects
of recombinant GH (Genotropin) administration in
critically ill ICU patients relatively early during ICU
stay in two placebo-controlled trials. Unexpectedly,
both trials demonstrated significantly increased mortality
in recombinant GH-treated patients (47 versus 25 % in
the Finnish study and 61 versus 26 % in the multinational
study). The mechanisms for increased mortality are
incompletely understood, but modulation of immune
function may play a role. Interestingly, Schols et al. [62]
reported the effects of the exogenous anabolic steroid
nadrolone in patients with stable COPD during an 8-week
pulmonary rehabilitation program. Patients (N = 217)
were randomized between placebo, placebo with high cal-
oric feeding, and nandrolone with high caloric feeding.
They found that nandrolone together with high caloric
feeding significantly improved inspiratory muscle strength.
These findings were more or less confirmed in a later trial
by the same group [63]. Although case series report the
use of anabolic steroids in difficult-to-wean patients [64],
no randomized studies have evaluated the safety and effi-
cacy of anabolic steroids in ICU patients with respiratory
muscle weakness. Accordingly, anabolic hormones should
not be used in the early stage of ICU admission but may
have a role in more chronic and stable ICU patients with
respiratory muscle weakness and who are difficult to wean
from the ventilator.
Positive inotropes
In addition to atrophy, dysfunction of the remaining
muscle fibers has been demonstrated in critically ill pa-
tients [4]. Accordingly, optimizing contractility using
positive inotropes seems a reasonable approach in these
patients. ß-Adrenoreceptor agonists indeed exhibit a
direct positive inotropic effect on the diaphragm muscle
in vitro by increasing intracellular calcium influx. The ef-
fects of β2 adrenoreceptor agonists on respiratory muscle
function in vivo are, however, controversial. Albuterol
(oral) did not affect fatigability of the diaphragm in healthy
subjects. However, fenoterol (oral) delayed the develop-
ment of diaphragm fatigue in healthy volunteers subjected
to inspiratory loading. In mechanically ventilated COPD
patients with respiratory failure, respiratory muscle
function significantly improved after dopamine infusion,
probably by augmentation of diaphragm blood flow and
improved cardiac output. Currently the administration of
ß-adrenoreceptor agonists cannot be recommended to
improve respiratory muscle function in ICU patients.
Muscle fibers isolated from the diaphragm of ICU
patients display decreased maximal force-generating
capacity, indicating intrinsic muscle weakness [11]. In
fast-twitch diaphragm fibers the reduction of sub-maximal
force generation even exceeds the loss of maximal
force-generating capacity [4]. This implies that these
fibers require more calcium to generate normal force
levels, i.e., their sensitivity to calcium is reduced. Calcium
sensitizers have been developed to treat similar pathology
of cardiac muscle [65, 66]. Currently, levosimendan is
the only calcium sensitizer approved for use in humans
(>50 countries worldwide). Experimental studies have
shown that levosimendan improves calcium sensitivity of
diaphragm muscle fibers from patients with COPD [67].
Moreover, a recent double-blind, randomized, crossover
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study demonstrated that administration of levosimendan
improved neuromechanical efficiency by >20 % and
prevented contractile fatigue during a diaphragm-loading
task in healthy subjects [68]. A randomized clinical trial
(ClinicalTrials.gov identifier NCT01721434) is currently
investigating whether levosimendan indeed facilitates lib-
eration from the ventilator. In contrast to levosimendan,
the effectiveness of other calcium sensitizers has so far
only been studied in vitro. For example, exposure to EMD
57033 (a troponin activator) partially restored calcium
sensitivity in diaphragm fibers isolated from piglets after
5 days of mechanical ventilation [69]. Furthermore, in dia-
phragm fibers from critically ill patients, CK-2066260
completely restores calcium sensitivity [4].
Taken together, calcium sensitizers might exert an ener-
getically beneficial effect on diaphragm work [67]. When
less calcium is needed to maintain force generation,
muscle work becomes more efficient [68] and could
improve respiratory muscle contractility in critically ill
patients. However, further clinical trials are needed to
prove the benefits of the calcium sensitizers in ICU
patients with respiratory muscle weakness.
Future developments
Modulation of inflammation
Activation of pro-inflammatory pathways is associated
with respiratory muscle weakness [70–73]. Therefore,
modulation of the inflammatory response to combat re-
spiratory muscle dysfunction has been a focus of interest
in recent experimental studies [71, 74, 75]. We demon-
strated, for instance, that interleukin (IL)-6 plays an im-
portant role in the loss of contractile proteins in muscle
fibers exposed to plasma from septic shock patients [71].
However, diaphragm fiber atrophy due to disuse in brain
death patients was not associated with upregulation of
IL-6 [10]. IL-10 is an interleukin with anti-inflammatory
properties [76]. In a murine model of Pseudomonas
aeruginosa pneumonia, diaphragm dysfunction was at-
tenuated after experimental IL-10 administration [76].
During critical illness with subsequent inflammatory
status, nuclear factor (NF)-κB is the key factor for
transcription of several cytokines [77]. Recently, evidence
was found that inhibition of NF-κB in endotoxemic mice
protects against diaphragm muscle weakness, probably due
to decreased generation of pro-inflammatory cytokines
[75]. Proteolytic pathways can be activated through Toll-
like receptor (TLR)-4, present in muscle plasma membrane
[74]. TLRs are essential receptors in recognizing microbes
and initiating an inflammatory immune response [78]. In
TLR-4 knockout mice, loss of diaphragm contractile pro-
tein associated with controlled mechanical ventilation was
attenuated compared with wild-type mice [74]. In a large
clinical trial the TLR-4 antagonist eritoran did not, how-
ever, improve outcome in patients with severe sepsis or
septic shock (±80 % on mechanical ventilation) [79].
Nevertheless, neither skeletal muscle function nor duration
of mechanical ventilation was assessed in this trial.
Traditionally, steroids are associated with myopathy,
atrophy, and dysfunction of the respiratory muscles
[80–82]. However, the final effects appear to be dose- and
time-dependent, at least in experimental studies. For
instance, Maes et al. [83] demonstrated that “low-dose”
(5 mg/kg) methylprednisolone exacerbated ventilator-
induced diaphragm dysfunction in rats, whereas a high
dose (30 mg/kg) protected against the deleterious effects
of controlled mechanical ventilation on diaphragm
function. In ICU patients the effect of steroids on muscle
function are conflicting [84–86]. However, no study has
prospectively evaluated the effects of corticosteroids on
respiratory muscle function in ventilated ICU patients.
In conclusion, despite the encouraging data that modu-
lation of inflammation improves respiratory muscle func-
tion in animals, data in humans are scarce and, where
present, disappointing.
Modulation of proteolytic pathways
Since activation of proteolytic systems plays a key role
in the development of respiratory muscle dysfunction
during critical illness, several experimental studies
have investigated the effect of specific inhibitors. For
instance, in rats exposed to 24 h of mechanical ventilation,
bortezomib treatment partially prevented the reduction of
diaphragm force and atrophy [58]. These small positive ef-
fects were probably mediated by the ability of bortezomib
to indirectly reduce caspase-3 activity [57]. Proteasomes
are only able to process myofilaments that have been
cleaved from the sarcomere by enzymes like caspases and
calpains [87]. Accordingly, inhibition of the proteasome
alone is not expected to have substantial effects on muscle
function as this would leave the muscle cell with only un-
processed, but cleaved, myofilaments. Furthermore, con-
sidering the basic housekeeping cell functions of the
proteasome, it is no surprise that the clinical application
of bortezomib is accompanied by serious toxic adverse
events, such as cytopenia and peripheral neuropathy [88].
Finally, although several compounds targeting proteolytic
pathways upstream of the proteasome have a high poten-
tial to prevent the development of diaphragm weakness,
this does not necessarily imply that these agents can also
improve function of the weakened diaphragm. Neverthe-
less, modulation of the proteolytic system is a potentially
interesting target to modulate loss of respiratory muscle
function due to controlled mechanical ventilation.
Conclusion
Weakness of the respiratory muscles frequently develops
in the ICU patient and is associated with adverse outcome,
including prolonged mechanical ventilation. Despite the
Schellekens et al. Critical Care  (2016) 20:103 Page 6 of 9
high incidence and clinical impact of ICU-acquired
respiratory muscle dysfunction, no specific preventive
or therapeutic interventions have been tested in large
randomized controlled trials. Therefore, we should
rely on interventions that seem reasonable from a
physiological perspective or are supported by small
clinical studies. As pointed out in Fig. 2, interventions
could be subdivided into three categories: prevention
of respiratory muscle dysfunction; therapeutic strat-
egies that aim to improve respiratory muscle function;
and so-called rescue interventions that should only be
applied in exceptional cases and only after discussion
with the patient or primary decision makers.
Preventive strategies should limit development of
disuse atrophy and muscle damage. We suggest using
techniques that monitor diaphragm muscle function
[21, 22] to confirm a physiologically acceptable level
of diaphragm contractility and allow the clinician to
optimize ventilator settings in order to improve pa-
tient–ventilator interaction. Drugs with potential side
effects on skeletal muscle, in particular corticoste-
roids and muscle relaxants, should be avoided when
appropriate.
Once ICU-acquired weakness has developed, a
combined program of respiratory muscle endurance
training and strength training should be considered.
Endurance training can be instituted using progressive
weaning trials and strength training by using a device
for variable inspiratory threshold loading connected
to the endotracheal tube [46]. Use of respiratory muscle
positive inotropes, in particular levosimendan, is the
subject of a current randomized controlled trial
(NCT01721434) and not currently recommended for
difficult-to-wean patients.
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